From serendipity to intention: development of brain penetrant PARP1 selective inhibitors
Clin Cancer Res. 2024 Jan 22. doi: 10.1158/1078-0432.CCR-23-3571. Online ahead of print.ABSTRACTPrimary and secondary brain tumors cause significant mortality and constitute an important unmet need. The development of AZD9574, a brain-penetrant, PARP1 selective inhibitor, with favorable pharmacologic properties and intriguing preclinical activity, has led to an ongoing clinical trial evaluating it alone and in combination with temozolomide or antibody drug conjugates.PMID:38251977 | DOI:10.1158/1078-0432.CCR-23-3571
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Filipa Lynce Nancy U Lin Source Type: research
More News: Brain | Brain Cancers | Brain Tumor | Cancer | Cancer & Oncology | Clinical Trials | Neurology | Temodar